Turofexorate Isopropyl (XL335)

Catalog No.S2694

Turofexorate Isopropyl (XL335) is a potent, selective FXR agonist with EC50 of 4 nM, highly selective versus other nuclear receptors, such as LXR, PPAR, ER and etc. Phase 1.

Price Stock Quantity  
USD 300 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Turofexorate Isopropyl (XL335) Chemical Structure

Turofexorate Isopropyl (XL335) Chemical Structure
Molecular Weight: 438.47

Validation & Quality Control

1 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Turofexorate Isopropyl (XL335) is available in the following compound libraries:

Product Information

  • Compare FXR Agonists
    Compare FXR Products
  • Turofexorate Isopropyl (XL335) Mechanism

Product Description

Biological Activity

Description Turofexorate Isopropyl (XL335) is a potent, selective FXR agonist with EC50 of 4 nM, highly selective versus other nuclear receptors, such as LXR, PPAR, ER and etc. Phase 1.
Targets FXR [1]
IC50 4 nM(EC50)
In vitro WAY-362450 binds to the ligand-binding domain (LBD) of human FXR. WAY-362450 resides in a predominately hydrophobic pocket with only a few polar atoms making contact with WAY-362450. WAY-362450 promotes transcription of the human BSEP, human SHP, and mouse IBABP genes utilizing reporter constructs with EC50 of 17, 230, and 33 nM, respectively in promoter assays. WAY-362450 at concentration of 1 μM significantly induces mRNAs encoding for BSEP, SHP, and IBABP in human cell cultures to 13-, 2-, and 20-fold, respectively. [1] WAY-362450 at concentration of 1 μM suppresses interleukin-6-induced CRP expression in human Hep3B hepatoma cells, and the inhibitory effect is attenuated when knockdown of FXR by short interfering RNA.
In vivo WAY-362450 administrated intravenously or orally at does of 3 mg/kg in rats with a protracted half-life of 25 h, modest volume of distribution, and low clearance of 3.3 L/kg. WAY-362450 administered orally at dose of 10 mg/kg in normal C57bl/6 mice for a period of 7 days significantly lowers triglycerides to 62.0 ± 6.4 mg/dL and total cholesterol to 78.1 ± 5.0 mg/dL. WAY-362450 administered orally at dose of 1 and 3 mg/kg daily for 6 weeks in LDLR−/− mice, triglycerides is lowered by 19% and 39%, respectively, total cholesterol is lowered by 23% and 50%, respectively and lesion formation by 18% and 36%, respectively. [1] WAY-362450 intraperitoneally administrated at dose of 30 mg/kg daily for 4 days in wild type C57BL/6 mice attenuates lipopolysaccharide-induced serum amyloid P component and serum amyloid A3 mRNA levels in the liver. [3] WAY-362450 orally administered at dose of 30 mg/kg/day for 4 weeks in adult male C57BL/6 mice reduces inflammatory cell infiltration and hepatic fibrosis, the reduction in inflammatory cell infiltration correlates with deceased serum levels of keratinocyte derived chemokine (mKC) and MCP 1 and decreased hepatic gene expression of MCP-1 and VCAM-1, and the reduction of hepatic fibrosis by WAY-362450 treatment corresponded to a reduction in hepatic gene expression of fibrosis markers. [3] WAY-362450 administrated orally at dose of 30mg/kg in LDLR−/− and apoE−/− mice blocks diet-induced hypertriglyceridemia and elevations of non-HDL cholesterol and produced a near complete inhibition of aortic lesion formation, WAY-362450 also induced small heterodimer partner (SHP) expression and repressed cholesterol 7α-hydroxylase (CYP7A1) and sterol 12 α-hydroxylase (CYP8B1) expression. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Cross-reactivity Studies The selectivity of 6m is evaluated using a panel of nuclear receptor expression plasmids in the forms of wild type receptors or chimeric receptors with Gal-DBD and NHR LBD transiently transfected to CV-1 cells in tissue culture flasks with the NHR responsive luciferase reporters. Except VDR assay, it is a two hybrid assay that measure the interaction of VP16 fused VDR-LBD and Gal-SRC1. The cells are harvested after 6 h transfection and seeded to the assay plates with diluted testing WAY-362450. Different than the agonist assay, the antagonist assay is carried out the in presence of an agonist at concentration of EC75. After 18 h of incubation, the media is removed from the plates and the lucifaerase activity is determined using the luciferase substrate. As shown in Tables S4-S5, compound 6m is highly selective, as little or no significant cross-reactivity with other nuclear hormone receptors is observed at concentrations up to 10 μM

Animal Study: [1]

Animal Models Seven week old male C57bl/6 mice
Formulation NMP:Solutol:PEG400:H2O, 10:10:40:40
Dosages 10 mg/kg
Administration Administrated orally once daily in the morning for a period of 7 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Flatt B, et al. J Med Chem, 2009, 52(4), 904-907.

[2] Zhang S, et al. J Hepatol, 2009, 51(2), 380-388.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT00509756 Terminated Healthy Wyeth is now a wholly owned subsidiary of Pfizer November 2007 Phase 1
NCT00499629 Completed Healthy Wyeth is now a wholly owned subsidiary of Pfizer October 2007 Phase 1

Chemical Information

Download Turofexorate Isopropyl (XL335) SDF
Molecular Weight (MW) 438.47
Formula

C25H24F2N2O3

CAS No. 629664-81-9
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms Fxr 450
Solubility (25°C) * In vitro DMSO 33 mg/mL warming (75.26 mM)
Ethanol 2 mg/mL (4.56 mM)
Water <1 mg/mL
In vivo NMP+polyethylene glycol 300 (10+90, v+v) 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (E)-isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related FXR Products

  • Obeticholic Acid

    Obeticholic Acid is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. Phase 3.

  • CB-839

    CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1.

  • GKT137831

    GKT137831 is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Phase 2.

  • GW4064

    GW4064 is an agonist of farnesoid X receptor (FXR) with EC50 of 65 nM in CV1 cell line.

  • Lithocholic acid

    Lithocholic acid is a toxic secondary bile acid, causes intrahepatic cholestasis, has tumor-promoting activity, its toxic effect can be protected after it activates the vitamin D receptor, PXR and FXR.

  • H 89 2HCl

    H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II.

  • Puromycin 2HCl

    Puromycin 2HCl is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.

  • Cyclosporin A

    Cyclosporin A is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.

  • Dexamethasone (DHAP)

    Dexamethasone (DHAP) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.

  • Cyclophosphamide Monohydrate

    Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA.

Recently Viewed Items

Tags: buy Turofexorate Isopropyl (XL335) | Turofexorate Isopropyl (XL335) supplier | purchase Turofexorate Isopropyl (XL335) | Turofexorate Isopropyl (XL335) cost | Turofexorate Isopropyl (XL335) manufacturer | order Turofexorate Isopropyl (XL335) | Turofexorate Isopropyl (XL335) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us